Overview

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Status:
Active, not recruiting
Trial end date:
2025-09-17
Target enrollment:
Participant gender:
Summary
This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie
Treatments:
Upadacitinib